Genmab A/S
Genmab A/S (GMAB) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
gmab · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Genmab A/S (GMAB) measures how much investors pay for each dollar of the company's trailing earnings. GMAB's current PE ratio of 18.72x is calculated by dividing its stock price of $25.15 by its TTM earnings per share of $13.36. −40.5% discount vs 5Y avg 31.5x
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2006 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 13 fiscal years · Front-end computedMinQ1 · 25%44.7x
MedianQ3 · 75%96.0x
Max
At 18.72x, GMAB's current P/E is lower than in 8% of its annual fiscal year readings over the past 13 years — historically low.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Genmab A/SYou GMAB | $15.4B | 18.72x | -2.2% | $13.36 |
 Quest Diagnostics Incorporated DGX | $22.2B | 19.42x | +1.5% | $8.94 |
 Exelixis, Inc. EXEL | $13.2B | 15.12x | -21.0% | $2.88 |
 Illumina, Inc. ILMN | $24.6B | 24.52x | +28.1% | $5.48 |
 Incyte Corporation INCY | $20.5B | 14.98x | -21.7% | $6.59 |
 Roivant Sciences Ltd. ROIV | $20.6B | N/A | — | -$0.43 |
 Royalty Pharma plc RPRX | $24.0B | 21.65x | +13.1% | $1.79 |
Industry Average 5 peers with valid PE | — | 19.14x | baseline | — |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | 19.86x | $1.55 | +60.4% | |
2024-12-31 FY2024 | 12.39x | $12.14 | -62.0% | |
2023-12-31 FY2023 | 32.56x | $6.60 | -7.8% | |
2022-12-31 FY2022 | 35.30x | $8.34 | -38.3% | |
2021-12-31 FY2021 | 57.19x | $4.52 | +68.6% | |
2020-12-31 FY2020 | 33.93x | $7.30 | -21.6% | |
2019-12-31 FY2019 | 43.26x | $3.44 | -3.1% | |
2018-12-31 FY2018 | 44.66x | $2.40 | -23.8% | |
2017-12-31 FY2017 | 58.64x | $1.81 | -0.8% | |
2016-12-31 FY2016 | 59.10x | $1.98 | -16.2% |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Genmab A/S (GMAB) measures how much investors pay for each dollar of the company's trailing earnings. GMAB's current PE ratio of 18.72x is calculated by dividing its stock price of $25.15 by its TTM earnings per share of $13.36.
Frequently asked questions
GMAB pe ratio · 6 questionsGMAB's current PE ratio is 18.72x as of 2026-06-08, based on a stock price of $25.15 and TTM EPS of $13.36. Data sourced from Financial Modeling Prep via GMAB's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Genmab A/S SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08